Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration

Summary by Eastern Progress
REDMOND, Wash., Oct. 13, 2025 /PRNewswire/ -- SystImmune, Inc., a clinical-stage biotechnology company, today announced the treatment of the first patient in the IZABRIGHT-Breast01 study (NCT06926868), a global Ph2/3 registrational study of izalontamab brengitecan (iza-bren) in previously untreated triple negative…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

endpoints.newsendpoints.news

SystImmune’s $250M milestone; Teva’s Uzedy approved to treat bipolar disorder

Plus, news about Avidity, Biophytis, the Novo Nordisk Foundation, ADC Therapeutics and Apogee Therapeutics: 💸 SystImmune to get $250M from Bristol Myers Squibb: The milestone payment is the result of the ...

Read Full Article
Eastern ProgressEastern Progress

SystImmune to Receive Milestone Payment from Bristol Myers Squibb Under Iza-Bren Collaboration

REDMOND, Wash., Oct. 13, 2025 /PRNewswire/ -- SystImmune, Inc., a clinical-stage biotechnology company, today announced the treatment of the first patient in the IZABRIGHT-Breast01 study (NCT06926868), a global Ph2/3 registrational study of izalontamab brengitecan (iza-bren) in previously untreated triple negative…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Eastern Progress broke the news in on Monday, October 13, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Novo Nordisk icon

Novo Nordisk

United States icon

United States

News
For You
SearchBlindspotLocal